Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
THOR's Cash to Debt is ranked higher than
95% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. THOR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
THOR' s Cash to Debt Range Over the Past 10 Years
Min: 0.94  Med: 41.05 Max: No Debt
Current: No Debt
Equity to Asset 0.83
THOR's Equity to Asset is ranked higher than
82% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. THOR: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
THOR' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.80 Max: 0.91
Current: 0.83
0.39
0.91
Interest Coverage 4167.15
THOR's Interest Coverage is ranked higher than
54% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 481.81 vs. THOR: 4167.15 )
Ranked among companies with meaningful Interest Coverage only.
THOR' s Interest Coverage Range Over the Past 10 Years
Min: 3.82  Med: 16.39 Max: 9999.99
Current: 4167.15
3.82
9999.99
F-Score: 5
Z-Score: 16.68
M-Score: -2.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.20
THOR's Operating margin (%) is ranked higher than
77% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. THOR: 11.20 )
Ranked among companies with meaningful Operating margin (%) only.
THOR' s Operating margin (%) Range Over the Past 10 Years
Min: -0.94  Med: 13.61 Max: 27.01
Current: 11.2
-0.94
27.01
Net-margin (%) 8.01
THOR's Net-margin (%) is ranked higher than
72% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. THOR: 8.01 )
Ranked among companies with meaningful Net-margin (%) only.
THOR' s Net-margin (%) Range Over the Past 10 Years
Min: 1.38  Med: 9.10 Max: 16.92
Current: 8.01
1.38
16.92
ROE (%) 5.90
THOR's ROE (%) is ranked higher than
59% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. THOR: 5.90 )
Ranked among companies with meaningful ROE (%) only.
THOR' s ROE (%) Range Over the Past 10 Years
Min: 0.85  Med: 6.80 Max: 11.87
Current: 5.9
0.85
11.87
ROA (%) 4.93
THOR's ROA (%) is ranked higher than
67% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. THOR: 4.93 )
Ranked among companies with meaningful ROA (%) only.
THOR' s ROA (%) Range Over the Past 10 Years
Min: 0.54  Med: 5.24 Max: 9.84
Current: 4.93
0.54
9.84
ROC (Joel Greenblatt) (%) 35.42
THOR's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. THOR: 35.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
THOR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 5.24  Med: 42.10 Max: 86.09
Current: 35.42
5.24
86.09
Revenue Growth (3Y)(%) 7.60
THOR's Revenue Growth (3Y)(%) is ranked higher than
66% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. THOR: 7.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
THOR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.1  Med: 14.20 Max: 71.9
Current: 7.6
-2.1
71.9
EBITDA Growth (3Y)(%) -11.60
THOR's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. THOR: -11.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
THOR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.6  Med: 5.25 Max: 133.5
Current: -11.6
-11.6
133.5
EPS Growth (3Y)(%) -9.50
THOR's EPS Growth (3Y)(%) is ranked lower than
68% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. THOR: -9.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
THOR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.2  Med: 16.90 Max: 196.2
Current: -9.5
-66.2
196.2
» THOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

THOR Guru Trades in Q1 2015

Manning & Napier Advisors, Inc 1,219,930 sh (-34.32%)
» More
Q2 2015

THOR Guru Trades in Q2 2015

Jim Simons 202,839 sh (New)
Manning & Napier Advisors, Inc 1,066,760 sh (-12.56%)
» More
Q3 2015

THOR Guru Trades in Q3 2015

Mario Gabelli 298,800 sh (New)
Manning & Napier Advisors, Inc Sold Out
Jim Simons 144,639 sh (-28.69%)
» More
Q4 2015

THOR Guru Trades in Q4 2015

Jim Simons Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with THOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Thoratec Corp

Mario Gabelli Comments on Thoratec Corp - Oct 19, 2015

Thoratec Corp. (NASDAQ:THOR)(2.1%) (THOR – $63.26 – NASDAQ), headquartered in Pleasanton, California, designs, manufactures and sells products to treat the full range of clinical needs for patients suffering from advanced heart failure. On July 22, 2015, St. Jude Medical announced that it would acquire the company for $63.50 cash per share in a merger worth $3.4 billion. Following regulatory and shareholder approvals, the transaction is expected to close in the fourth quarter of 2015.



From Mario Gabelli (Trades, Portfolio)'s third quarter 2015 ABC Fund commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Thoratec Corp

Mario Gabelli Comments on Thoratec Corp Guru stock highlight
Thoratec Corp. (NASDAQ:THOR)(2.1%) (THOR – $63.26 – NASDAQ), headquartered in Pleasanton, California, designs, manufactures and sells products to treat the full range of clinical needs for patients suffering from advanced heart failure. On July 22, 2015, St. Jude Medical announced that it would acquire the company for $63.50 cash per share in a merger worth $3.4 billion. Following regulatory and shareholder approvals, the transaction is expected to close in the fourth quarter of 2015. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 90.20
THOR's P/E(ttm) is ranked lower than
93% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. THOR: 90.20 )
Ranked among companies with meaningful P/E(ttm) only.
THOR' s P/E(ttm) Range Over the Past 10 Years
Min: 19.97  Med: 57.36 Max: 541.28
Current: 90.2
19.97
541.28
Forward P/E 39.84
THOR's Forward P/E is ranked lower than
90% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 18.42 vs. THOR: 39.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 90.70
THOR's PE(NRI) is ranked lower than
92% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 27.40 vs. THOR: 90.70 )
Ranked among companies with meaningful PE(NRI) only.
THOR' s PE(NRI) Range Over the Past 10 Years
Min: 20.06  Med: 57.59 Max: 527.75
Current: 90.7
20.06
527.75
P/B 5.06
THOR's P/B is ranked lower than
90% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. THOR: 5.06 )
Ranked among companies with meaningful P/B only.
THOR' s P/B Range Over the Past 10 Years
Min: 1.75  Med: 2.99 Max: 5.06
Current: 5.06
1.75
5.06
P/S 7.27
THOR's P/S is ranked lower than
97% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. THOR: 7.27 )
Ranked among companies with meaningful P/S only.
THOR' s P/S Range Over the Past 10 Years
Min: 2.7  Med: 4.45 Max: 7.27
Current: 7.27
2.7
7.27
PFCF 35.28
THOR's PFCF is ranked lower than
55% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 34.47 vs. THOR: 35.28 )
Ranked among companies with meaningful PFCF only.
THOR' s PFCF Range Over the Past 10 Years
Min: 12.79  Med: 27.59 Max: 2111
Current: 35.28
12.79
2111
POCF 33.07
THOR's POCF is ranked lower than
73% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 19.47 vs. THOR: 33.07 )
Ranked among companies with meaningful POCF only.
THOR' s POCF Range Over the Past 10 Years
Min: 11.81  Med: 25.55 Max: 175.92
Current: 33.07
11.81
175.92
EV-to-EBIT 60.44
THOR's EV-to-EBIT is ranked lower than
87% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. THOR: 60.44 )
Ranked among companies with meaningful EV-to-EBIT only.
THOR' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.1  Med: 32.90 Max: 167.9
Current: 60.44
10.1
167.9
EV-to-EBITDA 46.91
THOR's EV-to-EBITDA is ranked lower than
88% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 16.11 vs. THOR: 46.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
THOR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 46.91
Current: 46.91
0
46.91
PEG 90.70
THOR's PEG is ranked lower than
99% of the 68 Companies
in the Global Medical Devices industry.

( Industry Median: 3.39 vs. THOR: 90.70 )
Ranked among companies with meaningful PEG only.
THOR' s PEG Range Over the Past 10 Years
Min: 0.54  Med: 3.17 Max: 512.38
Current: 90.7
0.54
512.38
Shiller P/E 89.60
THOR's Shiller P/E is ranked lower than
92% of the 72 Companies
in the Global Medical Devices industry.

( Industry Median: 31.42 vs. THOR: 89.60 )
Ranked among companies with meaningful Shiller P/E only.
THOR' s Shiller P/E Range Over the Past 10 Years
Min: 35.26  Med: 70.53 Max: 140.92
Current: 89.6
35.26
140.92
Current Ratio 5.54
THOR's Current Ratio is ranked higher than
80% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. THOR: 5.54 )
Ranked among companies with meaningful Current Ratio only.
THOR' s Current Ratio Range Over the Past 10 Years
Min: 1.9  Med: 7.65 Max: 13.05
Current: 5.54
1.9
13.05
Quick Ratio 4.68
THOR's Quick Ratio is ranked higher than
79% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. THOR: 4.68 )
Ranked among companies with meaningful Quick Ratio only.
THOR' s Quick Ratio Range Over the Past 10 Years
Min: 1.1  Med: 6.24 Max: 11.18
Current: 4.68
1.1
11.18
Days Inventory 149.92
THOR's Days Inventory is ranked lower than
53% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. THOR: 149.92 )
Ranked among companies with meaningful Days Inventory only.
THOR' s Days Inventory Range Over the Past 10 Years
Min: 93.67  Med: 161.22 Max: 193.77
Current: 149.92
93.67
193.77
Days Sales Outstanding 61.72
THOR's Days Sales Outstanding is ranked higher than
61% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. THOR: 61.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
THOR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.2  Med: 64.44 Max: 74.52
Current: 61.72
51.2
74.52
Days Payable 46.64
THOR's Days Payable is ranked lower than
61% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. THOR: 46.64 )
Ranked among companies with meaningful Days Payable only.
THOR' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 46.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.10
THOR's Price/Net Cash is ranked lower than
75% of the 150 Companies
in the Global Medical Devices industry.

( Industry Median: 12.22 vs. THOR: 25.10 )
Ranked among companies with meaningful Price/Net Cash only.
THOR' s Price/Net Cash Range Over the Past 10 Years
Min: 4.25  Med: 18.19 Max: 1087.5
Current: 25.1
4.25
1087.5
Price/Net Current Asset Value 10.62
THOR's Price/Net Current Asset Value is ranked lower than
67% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 8.50 vs. THOR: 10.62 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
THOR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.61  Med: 10.00 Max: 362.5
Current: 10.62
2.61
362.5
Price/Tangible Book 8.32
THOR's Price/Tangible Book is ranked lower than
73% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 4.04 vs. THOR: 8.32 )
Ranked among companies with meaningful Price/Tangible Book only.
THOR' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.33  Med: 6.39 Max: 310.71
Current: 8.32
2.33
310.71
Price/Projected FCF 2.34
THOR's Price/Projected FCF is ranked lower than
66% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. THOR: 2.34 )
Ranked among companies with meaningful Price/Projected FCF only.
THOR' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.06  Med: 2.19 Max: 12.75
Current: 2.34
1.06
12.75
Price/DCF (Earnings Based) 3.19
THOR's Price/DCF (Earnings Based) is ranked lower than
74% of the 43 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. THOR: 3.19 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.63
THOR's Price/Median PS Value is ranked lower than
84% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. THOR: 1.63 )
Ranked among companies with meaningful Price/Median PS Value only.
THOR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.69  Med: 1.11 Max: 23.14
Current: 1.63
0.69
23.14
Price/Graham Number 5.73
THOR's Price/Graham Number is ranked lower than
79% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. THOR: 5.73 )
Ranked among companies with meaningful Price/Graham Number only.
THOR' s Price/Graham Number Range Over the Past 10 Years
Min: 1.87  Med: 3.72 Max: 12.72
Current: 5.73
1.87
12.72
Earnings Yield (Greenblatt) (%) 1.70
THOR's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. THOR: 1.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
THOR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 3.00 Max: 9.9
Current: 1.7
0.6
9.9
Forward Rate of Return (Yacktman) (%) -5.30
THOR's Forward Rate of Return (Yacktman) (%) is ranked lower than
72% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 5.28 vs. THOR: -5.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
THOR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -7.2  Med: 8.60 Max: 45.7
Current: -5.3
-7.2
45.7

More Statistics

Revenue(Mil) $484
EPS $ 0.70
Short Percentage of Float4.82%
52-Week Range $25.04 - 63.51
Shares Outstanding(Mil)54.80

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 489 530
EPS($) 1.13 1.60
EPS without NRI($) 1.13 1.60

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TL1.Germany,
Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Aachen Innovative Solutions GmbH, AbioMed, Inc., Berlin Heart GmbH, HeartWare International Inc., Jarvik Heart, Inc., Maquet Cardiovascular, LLC (a division of Getinge AB), MicroMed Technology, Inc., Sun Medical Technology Research Corporation, SynCardia Systems, Inc., and Terumo Heart, Inc. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.
» More Articles for THOR

Headlines

Articles On GuruFocus.com
The Gabelli ABC Fund Merger and Arbitrage Shareholder Commentary for Q4 Jan 29 2016 
Mario Gabelli Comments on Thoratec Corp Oct 19 2015 
5-year lows: Thoratec Corp, Brady Corp, General Cable Corp, and UTi Worldwide Inc. Aug 25 2014 
5-year lows: Mack-Cali Realty Corp, Thoratec Corp, Brady Corp, and EXCO Resources Inc. Aug 10 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Weekly Guru Bargains Highlights: CSTR, VRX, SAY, THOR, BVN Feb 12 2011 
Weekly Guru Bargains Highlights: SVU, MSI, THOR, JNY, AMLN Jan 23 2011 
Weekly Guru Bargains Highlights: DF, CLWR, THOR, VRX, ASIA Dec 26 2010 
Weekly Guru Bargains Highlights: TFSL, THOR, CISG, VRX, DLR Dec 18 2010 

More From Other Websites
[$$] St. Jude to Meet Profit View Jan 13 2016
Hedge Funds Have This To Say About Thoratec Corporation (THOR) Nov 20 2015
St. Jude Completes Acquisition of Thoratec for $3.3 Billion Oct 09 2015
THORATEC CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 08 2015
Thoratec Shareholders Approve St. Jude Medical's Acquisition Of Thoratec Oct 07 2015
Thoratec Shareholders Approve St. Jude Medical's Acquisition Of Thoratec Oct 07 2015
Thoratec Highlights Clinical Events From The European Association For Cardio-Thoracic Surgery... Oct 06 2015
Thoratec Highlights Clinical Events From The European Association For Cardio-Thoracic Surgery... Oct 06 2015
THORATEC CORP Files SEC form 8-K, Other Events Oct 01 2015
Verisk Analytics Set to Join the S&P 500; Joy Global to Join S&P MidCap 400 Sep 30 2015
Thoratec's HeartMate III CE Mark Trial Results Positive Sep 28 2015
HeartMate 3™ CE Mark Trial Meets Primary Endpoint Sep 27 2015
HeartMate 3™ CE Mark Trial Meets Primary Endpoint Sep 27 2015
Tiny Heart Pumps From Abiomed Save Lives, Lift Stock Sep 16 2015
Thoratec Issues Voluntary Device Correction Sep 14 2015
Thoratec Issues Voluntary Device Correction Sep 14 2015
Thoratec Initiates SHIELD II Clinical Study for HeartMate PHP Sep 07 2015
Thoratec Announces Start Of Shield II™ U.S. Clinical Trial Sep 04 2015
Thoratec Announces Start Of Shield II™ U.S. Clinical Trial Sep 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK